Monitor Intently (2)pentobarbital will minimize the level or result of suvorexant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Observe. Powerful CYP3A4 inducers may well decrease suvorexant efficacy; if greater suvorexant dose essential, never exceed 20 mg/day
pentobarbital will lessen the extent or effect of eletriptan by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Observe.
Stay away from coadministration of ganaxolone with moderate or solid CYP3A4 inducers. If coadministration unavoidable, take into account escalating ganaxolone dose; even so, usually do not exceed maximum day by day dose for fat.
pentobarbital will reduce the level or result of pantoprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Importance Not known.
Keep an eye on Intently (1)pentobarbital will lower the extent or impact of osilodrostat by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
Next oral or parenteral administration, barbiturates easily cross the placental barrier and so are dispersed throughout fetal tissues with maximum concentrations located in the placenta, fetal liver, and brain; fetal blood amounts solution maternal blood ranges adhering to parenteral administration
pentobarbital will minimize the extent or result of clozapine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep an eye on.
pentobarbital will decrease the extent or outcome of ramelteon by influencing hepatic enzyme CYP2C9/10 metabolism. Insignificant/Importance Not known.
If the buprenorphine dose is inadequate and also the CYP3A4 inducer cannot be decreased or discontinued, transition the patient again to the buprenorphine formulation that permits dose adjustments.
pentobarbital will lessen the level or impact of estradiol vaginal by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Check.
pentobarbital will minimize the level or influence of atazanavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Importance read more Unknown.
pentobarbital will reduce the level or effect of cariprazine by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
pentobarbital will minimize the extent or effect of lumacaftor/ivacaftor by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.
pentobarbital will minimize the level or effect of vinorelbine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Importance Unfamiliar.